These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 22323134)

  • 1. Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanisms.
    Liu T; Bitan G
    ChemMedChem; 2012 Mar; 7(3):359-74. PubMed ID: 22323134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
    Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
    J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases.
    Wilhelmus MM; van Dam AM; Drukarch B
    Eur J Pharmacol; 2008 May; 585(2-3):464-72. PubMed ID: 18417122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Congo red and protein aggregation in neurodegenerative diseases.
    Frid P; Anisimov SV; Popovic N
    Brain Res Rev; 2007 Jan; 53(1):135-60. PubMed ID: 16959325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein misfolding in neurodegenerative diseases.
    Agorogiannis EI; Agorogiannis GI; Papadimitriou A; Hadjigeorgiou GM
    Neuropathol Appl Neurobiol; 2004 Jun; 30(3):215-24. PubMed ID: 15175075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for the inhibition of protein aggregation in human diseases.
    Bartolini M; Andrisano V
    Chembiochem; 2010 May; 11(8):1018-35. PubMed ID: 20401887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
    Hol EM; Fischer DF; Ovaa H; Scheper W
    Expert Rev Neurother; 2006 Sep; 6(9):1337-47. PubMed ID: 17009921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
    Sas K; Robotka H; Toldi J; Vécsei L
    J Neurol Sci; 2007 Jun; 257(1-2):221-39. PubMed ID: 17462670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
    Barchet TM; Amiji MM
    Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases.
    Popovic N; Brundin P
    Int J Pharm; 2006 May; 314(2):120-6. PubMed ID: 16529886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications.
    Williams A; Jahreiss L; Sarkar S; Saiki S; Menzies FM; Ravikumar B; Rubinsztein DC
    Curr Top Dev Biol; 2006; 76():89-101. PubMed ID: 17118264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phthalocyanines as Molecular Scaffolds to Block Disease-Associated Protein Aggregation.
    Valiente-Gabioud AA; Miotto MC; Chesta ME; Lombardo V; Binolfi A; Fernández CO
    Acc Chem Res; 2016 May; 49(5):801-8. PubMed ID: 27136297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycyclic cage structures as lipophilic scaffolds for neuroactive drugs.
    Joubert J; Geldenhuys WJ; Van der Schyf CJ; Oliver DW; Kruger HG; Govender T; Malan SF
    ChemMedChem; 2012 Mar; 7(3):375-84. PubMed ID: 22307951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug targets for amyloidosis.
    Kolstoe SE; Wood SP
    Biochem Soc Trans; 2010 Apr; 38(2):466-70. PubMed ID: 20298204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein-misfolding diseases and chaperone-based therapeutic approaches.
    Chaudhuri TK; Paul S
    FEBS J; 2006 Apr; 273(7):1331-49. PubMed ID: 16689923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting oligomers in neurodegenerative disorders: lessons from α-synuclein, tau, and amyloid-β peptide.
    Gadad BS; Britton GB; Rao KS
    J Alzheimers Dis; 2011; 24 Suppl 2():223-32. PubMed ID: 21460436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases.
    Cheng B; Gong H; Xiao H; Petersen RB; Zheng L; Huang K
    Biochim Biophys Acta; 2013 Oct; 1830(10):4860-71. PubMed ID: 23820032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases.
    Hekmatimoghaddam S; Zare-Khormizi MR; Pourrajab F
    Biofactors; 2017 Nov; 43(6):737-759. PubMed ID: 26899445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.
    Meredith SC
    Ann N Y Acad Sci; 2005 Dec; 1066():181-221. PubMed ID: 16533927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.